• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Guardant Health Inc.

    2/24/25 4:19:02 PM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    S-8 1 d929918ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 24, 2025

    Registration No. 333-    

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Guardant Health, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   45-4139254

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    3100 Hanover Street

    Palo Alto, California

      94304
    (Address of Principal Executive Offices)   (Zip Code)

    2018 Incentive Award Plan

    2018 Employee Stock Purchase Plan

    (Full Title of the Plan)

    John Saia

    Chief Legal Officer and Corporate Secretary

    3100 Hanover Street

    Palo Alto, California, 94304

    (855) 698-8887

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Andrew Thorpe, Esq.

    Elena Vespoli, Esq.

    Gunderson Dettmer Stough Villeneuve

    Franklin & Hachigian, LLP

    One Bush Plaza

    Suite 1200

    San Francisco, California 94104

    Tel: (415) 978-9803

    Fax: (415) 978-9806

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an aggregate of an additional 4,795,700 shares of common stock of the Registrant issuable under the following employee benefit plans for which registration statements (File Nos. 333-227762, 333-236807, 333-253733, 333-263105, 333-270241 and 333-277312) of the Registrant on Form S-8 (the “Registration Statements”) are effective: (i) the Guardant Health, Inc. 2018 Incentive Award Plan which, as a result of the operation of an automatic annual increase provision therein, added 3,689,000 shares of common stock and (ii) the Guardant Health, Inc. 2018 Employee Stock Purchase Plan which, as a result of the operation of an automatic annual increase provision therein, added 1,106,700 shares of common stock.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON

    FORM S-8

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on October 10, 2018 (File No.  333-227762), March 2, 2020 (File No. 333-236807), March  1, 2021 (File No. 333-253733), February  28, 2022 (File No. 333-263105), March  2, 2023 (File No. 333-270241) and February  23, 2024 (File No. 333-277312) are incorporated by reference herein.


    EXHIBIT INDEX

     

    Exhibit

    Number

            Incorporated by Reference       
      

    Exhibit Description

       Form      Date      Exhibit     File
    Number
         Filed
    Herewith
      4.1    Amended and Restated Certificate of Incorporation.      8-K        10-9-18        3.1       001-38683     
      4.2    Amended and Restated Bylaws.      8-K        10-9-18        3.2       001-38683     
      5.1    Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.               X
     10.1    2018 Incentive Award Plan.      S-8        10-10-18        99.2 (a)      333-227762     
     10.2    Form of Stock Option Agreement under the 2018 Incentive Award Plan.      10-Q        8-7-24        10.2       001-38683     
     10.3    Form of Restricted Stock Award Agreement under the 2018 Incentive Award Plan.      S-1/A        9-21-18        10.9 (b)      333-227206     
     10.4    Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.      10-Q        8-7-24        10.3       001-38683     
     10.5    Forms of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.      10-Q        8-7-24        10.4       001-38683     
     10.6    2018 Employee Stock Purchase Plan.      S-8        10-10-18        99.3       333-227762     
     10.7    First Amendment to 2018 Employee Stock Purchase Plan.      10-K        3-29-19        10.4 (a)      001-38683     
     23.1    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.               X
     23.2    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.               X
     23.3    Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).               X
     24.1    Power of Attorney (incorporated by reference to the signature page hereto).               X
    107    Filing Fee Table.               X


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, California, on February 24, 2025.

     

    Guardant Health, Inc.
    By:   /s/ Michael Bell
      Michael Bell
      Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Helmy Eltoukhy, AmirAli Talasaz and Michael Bell and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.


    Signature

      

    Title

     

    Date

    /s/ Helmy Eltoukhy

    Helmy Eltoukhy

       Co-Chief Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors   February 24, 2025

    /s/ AmirAli Talasaz

    AmirAli Talasaz

      

    Co-Chief Executive Officer

    (Principal Executive Officer) and Director

      February 24, 2025

    /s/ Michael Bell

    Michael Bell

      

    Chief Financial Officer

    (Principal Accounting Officer and Principal Financial Officer)

      February 24, 2025

    /s/ Ian Clark

    Ian Clark

       Director   February 24, 2025

    /s/ Vijaya Gadde

    Vijaya Gadde

       Director   February 24, 2025

    /s/ Meghan Joyce

    Meghan Joyce

       Director   February 24, 2025

    /s/ Steve Krognes

    Steve Krognes

       Director   February 24, 2025

    /s/ Manuel Hidalgo Medina

    Manuel Hidalgo Medina

       Director   February 24, 2025

    /s/ Roberto Mignone

    Roberto Mignone

       Director   February 24, 2025

    /s/ Myrtle Potter

    Myrtle Potter

       Director   February 24, 2025

    /s/ Musa Tariq

    Musa Tariq

       Director   February 24, 2025
    Get the next $GH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    12/2/2025$130.00Overweight
    Morgan Stanley
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    9/22/2025$72.00Overweight
    Wells Fargo
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    More analyst ratings

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

    Partnership integrates Guardant's large-scale genomic data with Trial Library's AI-powered matching and navigation platform to expand equitable access to oncology clinical trials across the United States Collaboration seeks to broaden trial access for representative and underserved patient populations by uniting genomic insights with personalized navigation and support services Guardant Health (NASDAQ:GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States. The collaboration combines Guardant Heal

    12/11/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

    Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer o

    12/9/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

    Presentations highlight advancements in cancer recurrence detection with Guardant Reveal and real-time treatment response monitoring with Guardant360 Liquid Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD) and Guardant360 Liquid, the company's comprehensive multiomic profiling te

    12/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Talasaz Amirali disposed of 387,946 shares, acquired 387,946 shares and sold $10,505,474 worth of shares (100,000 units at $105.05) (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    12/10/25 9:33:24 PM ET
    $GH
    Medical Specialities
    Health Care

    Chief Information Officer Kalia Kumud sold $209,204 worth of shares (2,000 units at $104.60), decreasing direct ownership by 8% to 22,365 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    12/10/25 9:32:48 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel exercised 1,000 shares at a strike of $32.55 and sold $131,250 worth of shares (1,250 units at $105.00), decreasing direct ownership by 24% to 797 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    12/10/25 9:32:14 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    SEC Filings

    View All

    SEC Form 144 filed by Guardant Health Inc.

    144 - Guardant Health, Inc. (0001576280) (Subject)

    12/5/25 5:21:57 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    11/7/25 5:17:52 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Guardant Health Inc.

    424B5 - Guardant Health, Inc. (0001576280) (Filer)

    11/6/25 4:34:10 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Guardant Health with a new price target

    Morgan Stanley resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $130.00

    12/2/25 8:25:46 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

    9/25/25 8:22:52 AM ET
    $GH
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Guardant Health with a new price target

    Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

    9/22/25 8:30:36 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

    Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

    3/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Roberto A. Mignone Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

    10/24/24 5:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/8/24 10:46:38 AM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

    SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

    7/5/24 10:32:48 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Financials

    Live finance-specific insights

    View All

    Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40% Screeni

    10/29/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

    Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant

    10/26/25 3:01:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012

    10/9/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care